ArticleScience (New York, N.Y.)2016
Rapid development of a DNA vaccine for Zika virus.
2 registry-linked trialsOpen access · greenAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 245 papers.
0numbers the graph read from it
0cells of the map it votes in
245citing papers in PubMed
63.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, in Healthy Adults
VRC 705: A Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and Adolescents
Who cites it
245 citing papers in PubMed, 400 citations in OpenAlex.
- Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.Lancet (London, England) · 2018Trial
- Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.Lancet (London, England) · 2018Trial
- A Zika virus vaccine with E protein fusion loop mutations protects via CD8Nature microbiology · 2026Article
- Dengue vaccine: a hidden risk to Aedes aegypti control in Brazil.Osong public health and research perspectives · 2026Article
- Ten Years of Congenital Zika Syndrome: From Outbreak to a Decade of Clinical, Therapeutic, and Preventive Advances in a Tropical Disease Context.Tropical medicine and infectious disease · 2026Review
- Rational design of flavivirus E protein vaccine optimizes immunogenicity and mitigates antibody dependent enhancement risk.Nature communications · 2025Article
- Immunological and transcriptomic profile of chimeric live-attenuated Zika vaccine linked to protection in non-human primates.Nature communications · 2025Article
- The modified mRNA vaccine protects immunocompromised AG129 mice from lethal challenge and multi-tissue infection by Zika virus.Emerging microbes & infections · 2025Article
- Global research hotspots and trends in DNA vaccine research: A bibliometric and visualization study from 2014 to 2024.Human vaccines & immunotherapeutics · 2025Article
- Bioprofiling and vaccine development for Zika virus.Science China. Life sciences · 2025Review
- An updated review of Zika virus vaccine development.Clinical and experimental vaccine research · 2025Review
- Mouse strain-dependent neutralizing antibody responses to Zika virus vaccines.Journal of microbiology (Seoul, Korea) · 2025Article
- Review
- From Antibodies to Immunity: Assessing Correlates of Flavivirus Protection and Cross-Reactivity.Vaccines · 2025Review
- Review
- Efficacy of emergency maternal MVA-ZIKV vaccination in a rapid challenge model of lethal Zika infection.NPJ vaccines · 2025Article
- Latest advances and prospects in the pathogenesis, animal models, and vaccine research of severe fever with thrombocytopenia syndrome virus.Frontiers in immunology · 2025Review
- A bivalent self-amplifying RNA vaccine against yellow fever and Zika viruses.Frontiers in immunology · 2025Article
- Comparison of Three Chimeric Zika Vaccine Prototypes Developed on the Genetic Background of the Clinically Proven Live-Attenuated Japanese Encephalitis Vaccine SAInternational journal of molecular sciences · 2024Article
- Animal Models, Therapeutics, and Vaccine Approaches to Emerging and Re-Emerging Flaviviruses.Viruses · 2024Review
185 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 7 institutions in 1 country.
Kimberly A DowdViral Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Sung-Youl KoVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Kaitlyn M MorabitoVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Eun Sung YangVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Rebecca S PelcViral Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Christina R DeMasoViral Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Leda R CastilhoVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Federal University of Rio de Janeiro, COPPE (Instituto Alberto Luiz Coimbra de Pós-Graduação e Pesquisa de Engenharia), Chemical Engineering Program, Rio de Janeiro, Rio de Janeiro, Brazil.
Peter AbbinkCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Michael BoydCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Ramya NityanandamCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
David N GordonViral Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
John Robert GallagherStructural Informatics Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Xuejun ChenVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
John-Paul ToddVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Yaroslav TsybovskyElectron Microscopy Laboratory, Cancer Research Technology Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Audray HarrisStructural Informatics Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Yan-Jang S HuangDepartment of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA.
Stephen HiggsDepartment of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA.
Dana L VanlandinghamDepartment of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA.
Hanne AndersenBioqual, Rockville, MD 20852, USA.
Mark G LewisBioqual, Rockville, MD 20852, USA.
Rafael De La BarreraTranslational Medicine Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
Kenneth H EckelsTranslational Medicine Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
Richard G JarmanViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
Martha C NasonBiostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852, USA.
Dan H BarouchCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Mario RoedererVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Wing-Pui KongVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
John R MascolaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Theodore C PiersonViral Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. piersontc@niaid.nih.gov bgraham@mail.nih.gov.
Barney S GrahamVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. piersontc@niaid.nih.gov bgraham@mail.nih.gov.
National Institute of Allergy and Infectious Diseases · USBeth Israel Deaconess Medical Center · USKansas State University · USNational Institutes of Health · USBioqual · USLeidos (United States) · USWalter Reed Army Institute of Research · US
Funding
Vaccine Research and Development for Endemic, Emerging, and Resurgent VirusesZIAAI005128 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KANEKIYO, MASARU · 2016 to 2025
$50.8MThe humoral response to Zika virus infection and vaccinationZIAAI001209 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI PIERSON, THEODORE · 2016 to 2025
$22.0MStructural Biology of Influenza EpitopesZIAAI001180 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI HARRIS, AUDRAY · 2013 to 2025
$12.7MCCR NIH HHS HHSN261200800001CIntramural NIH HHS ZIA AI005128NCI NIH HHS HHSN261200800001E
Abstract
Zika virus (ZIKV) was identified as a cause of congenital disease during the explosive outbreak in the Americas and Caribbean that began in 2015. Because of the ongoing fetal risk from endemic disease and travel-related exposures, a vaccine to prevent viremia in women of childbearing age and their partners is imperative. We found that vaccination with DNA expressing the premembrane and envelope proteins of ZIKV was immunogenic in mice and nonhuman primates, and protection against viremia after ZIKV challenge correlated with serum neutralizing activity. These data not only indicate that DNA vaccination could be a successful approach to protect against ZIKV infection, but also suggest a protective threshold of vaccine-induced neutralizing activity that prevents viremia after acute infection.
Indexed as
Immunogenicity, VaccineAnimalsAntibodies, NeutralizingFemaleMacaca mulattaMaleMiceVaccinationVaccines, DNAViral Envelope ProteinsViral LoadViral VaccinesViremiaZika VirusZika Virus InfectionAntibodies, NeutralizingprM protein, FlavivirusVaccines, DNAViral Envelope ProteinsViral Vaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT02996461ClinicalTrials.gov
NCT03110770ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.